Spero Therapeutics Q2 2024 GAAP EPS $(0.33) Beats $(0.38) Estimate, Sales $10.197M Beat $3.267M Estimate
Portfolio Pulse from Benzinga Newsdesk
Spero Therapeutics (NASDAQ:SPRO) reported Q2 2024 GAAP EPS of $(0.33), beating the $(0.38) estimate. Sales were $10.197M, significantly surpassing the $3.267M estimate. Despite a 43.48% increase in losses per share from last year, sales grew by 275.44%.
August 05, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spero Therapeutics reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.33) beating the $(0.38) estimate and sales of $10.197M surpassing the $3.267M estimate. Despite higher losses per share compared to last year, the significant increase in sales is a positive indicator.
The better-than-expected earnings and significant sales growth are likely to positively impact SPRO's stock price in the short term. Beating both EPS and sales estimates by a wide margin indicates strong performance and potential investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100